Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism by Kruse, Anja E et al.
Short Communication
Effect of cinacalcet cessation in renal transplant recipients
with persistent hyperparathyroidism
Anja E. Kruse, Ute Eisenberger, Felix J. Frey and Markus G. Mohaupt
Department of Nephrology and Hypertension, University of Berne, 3010 Berne, Switzerland
Abstract
Background. Persistent hyperparathyroidism after
renal transplantation affects bone and allografts.
Cinacalcet, a calcimimetic, reduces serum calcium
and PTH in renal transplant recipients with persistent
hyperparathyroidism. Here, we address the question
whether this effect of cinacalcet persists after
withdrawal.
Methods. Therefore, cinacalcet was stopped after 12
months treatment in 10 stable renal transplant
patients. Serum calcium, phosphate, PTH, creatinine
and cystatin C were monitored for 3 months.
Results. Serum calcium, normalized in nine patients
before cessation of cinacalcet (2.32 0.05mmol/l,
meanSEM), increased after 3 months of discontin-
uation by 0.17 0.04mmol/l, P< 0.05, but remained
within the normal range in eight patients. Compared
with the time point of cessation, PTH remained
unchanged or decreased further after 3 months without
therapy in six patients. Measurements of cystatin C
suggested an improvement of the glomerular filtration
rate after cessation in 9 out of 10 patients (1.55 0.09
vs 1.33 0.12mg/l, P< 0.01).
Conclusion. First, a beneficial effect of cinacalcet
beyond the duration of a 12-month therapy appears
to be present in some patients and second, the
previously suspected influence of cinacalcet therapy
on renal function is reversible. Thus, it is reasonable to
consider a trial of cinacalcet cessation to identify these
patients. The optimal time point for such a discontin-
uation is unknown. The present observations are
preliminary. They clearly require a prospective
randomized trial for definitive confirmation.
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Introduction
Secondary hyperparathyroidism is a common compli-
cation of renal failure and end-stage renal disease.
Despite normalization of renal function and normal
concentrations of 1.25-dihydroxyvitamin D after renal
transplantation, elevated parathormone (PTH) con-
centrations often persist, leading to markedly increased
serum calcium levels, decreased bone mass and
possibly perpetuating allograft nephropathy [1]. In
about one-third of the patients, hyperparathyroidism
does not completely resolve after transplantation. In
some of these patients, a surgical intervention is
hazardous and therefore medical treatment of interest.
In addition, parathyroidectomy is associated with a
decline in the glomerular filtration rate in some
patients [2,3].
Cinacalcet, a calcimimetic, has been reported to
reduce serum calcium and PTH concentrations in
renal transplant patients. So far, this has been
shown in about 40 patients, including our own
10 subjects [4–7]. Whether the beneficial effect of
cinacalcet persists in these patients after withdrawal
cannot be predicted on the basis of the various
mechanisms of action of calcimimetics. The initial
mechanisms considered for the calcimimetics were
decreased PTH secretion [8] and reduced parathyroid
gland hyperplasia [9]. More recently, Levi and
co-workers [10] presented evidence that calcimimetics
decrease PTH concentration because its transcript
levels are post-transcriptionally modified by a post-
translational regulation of the mRNA binding
protein AUF1.
In order to analyse whether a beneficial effect on
PTH and calcium concentrations persists after
prolonged therapy with a calcimimetic without affect-
ing renal function, the calcimimetic cinacalcet was
withdrawn after 1 year of treatment in 10 renal
transplant recipients with persistent hyperparathyroid-
ism. This approach is of interest, because contrary to
patients on haemodialysis the main stimuli for
hyperparathyroidism, hyperphosphataemia and hypo-
calcaemia in the presence of low concentrations of
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1.25-dihydroxyvitamin D are absent with stable renal
transplant function.
Subjects and methods
Fifteen renal transplant patients who were followed in our
unit received 30mg of cinacalcet once daily in the
evening for at least 1 year due to persistent hyperparathy-
roidism with hypercalcaemia. Thirteen were previously
evaluated and reported after beginning of therapy [4].
Because of unstable conditions due to neoplasia, gastro-
intestinal bleeding, recurrent infections and rejection,
five were not electable to be included in the
present study. In 10 stable renal transplant
patients (seven males, three females, aged 28–66 years)
cinacalcet therapy was discontinued and the patients
were followed for an additional 3 months without
therapy. Hyperparathyroidism was defined by increased
serum calcium concentrations, in the presence of elevated
PTH levels on dialysis not normalized 12 months after
renal transplantation, despite normal or increased
1.25-dihydroxyvitamin D levels. Cinacalcet treatment was
started 16–162 months (median 35 months) after renal
transplantation. All patients received prednisone at
doses up to 10mg/day and in addition nine were on
cyclosporine A and one on tacrolimus. Four patients were
given mycophenolate mofetil and two azathioprine.
Five patients were treated with 1.25-dihydroxyvitamin D
orally and two with cholecalciferol. This treatment
remained unchanged after stopping cinacalcet. One patient
received intravenous pamidronate every third month until
1 month before cinacalcet treatment was begun, but not
thereafter. Eight patients were on b–blockers, seven
on ACE-inhibitors, six on calcium channel blockers,
four on angiotensin II antagonists and four on loop
diuretics as antihypertensive therapy. Five patients had
ongoing hypertension with blood pressure 135/85mmHg.
In three patients the dosage of ACE-inhibitor or angioten-
sin II antagonist respectively was increased during
follow-up. In one patient, the loop diuretic torasemide
was slightly increased from 10 to 12.5mg daily. Two
patients were treated for diabetes, one with metformin,
one with insulin. Outpatient visits were scheduled the day
before cinacalcet withdrawal and 2 weeks, 2 months and
3 months after cinacalcet treatment was stopped.
Thereafter, the study was completed and the transplant
nephrologists followed the patients routinely. At month
nine after cessation of cinacalcet, the files from all 10
patients were reviewed again at a routinely scheduled visit
in our clinic.
The following parameters were assessed: PTH (intact),
1.25-dihydroxyvitamin D, calcium, phosphate, creatinine
and cystatin C in serum, calcium, phosphate and creatinine
in the urine; Cyclosporine A whole blood through levels as
well as office blood pressure. Concomitant medication and
medical events were recorded.
Statistical analyses were performed using SAS Inc. 9.1.
The ANOVA with Student–Newman–Keuls-test was
applied. Data are given as means SEM or as otherwise
indicated.
The study was approved by the local Ethical Review
Board. Informed consent was given by all patients.
Results
Effect of cinacalcet withdrawal on calcium, PTH,
1.25-dihydroxyvitamin D and phosphate
Serum calcium was well controlled in nine out of 10
patients before cessation of therapy (2.32 0.05mmol/
l, normal range: 2.10–2.55mmol/l) (Figure 1; month 0).
After cinacalcet withdrawal at 3 months, mean serum
calcium concentrations increased by 0.17 0.04mmol/
l (P< 0.05), but remained within the normal range in
eight out of 10 patients whereas reaching 2.6mmol/l in
the remaining two (Figure 1; month 3). Interestingly
serum calcium concentrations increased immediately
after cessation of cinacalcet as shown in Figure 1
(month 0.5) in all of the 10 patients, an effect followed
by a decline at month 2 in seven patients out of 10 and
at month 3 in nine out of 10 when compared with
month 0.5. Calciuria calculated as the calcium/creati-
nine ratio tended to increase 2 weeks after stopping
cinacalcet when compared with values obtained during
treatment (0.30 0.07 vs 0.25 0.06mmol calcium/
mmol creatinine), but did not change significantly at
any time point.
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Fig. 1. Mean ( SEM) serum concentrations of PTH, calcium and
phosphate before initiation (12), after 1 year of cinacalcet (0) and,
2 weeks (0.5), 2 months(2) and 3 months (3) after cessation of
cinacalcet. P< 0.05 vs month 0. Upper limits of normal ranges are
depicted by dotted lines.
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Serum concentrations of PTH tended to rise during
the initial 2 weeks after cessation of cinacalcet in eight
out of 10 patients (Figure 1; month 0 and 0.5).
Compared with the time point of cessation, PTH
levels remained unchanged or decreased further after 3
months without therapy in six patients. In two
patients, PTH remained below pre-treatment levels.
In the remaining two patients, PTH concentrations
rose to pre-treatment levels. Mean 1.25-dihydroxy-
vitamin D concentrations were 69.8 7.5 pmol/l
during treatment with cinacalcet and lower (P< 0.05)
than at week 2 (93.7 10.1 pmol/l), month 2
(105.8 13.5 pmol/l) and month 3 (101.3 11.7
pmol/l) after cessation of cinacalcet. Serum phosphate
concentrations (mean 1.03 0.07mmol/l at the end of
the treatment phase vs 0.96 0.06mmol/l after 3
months without) and calcium–phosphate products
(2.39 0.17 vs 2.40 0.16 mmol2/l2) did not change
after withdrawal of cinacalcet. Fractional urinary
phosphate excretion remained unaltered throughout
the 3 months of cinacalcet withdrawal.
Beyond the 3 months prospective study protocol the
patient files were reviewed for data at month 9 after
cessation of cinacalcet. At this time point, two patients
described as insufficiently controlled during the study
period were again on cinacalcet. Of the remaining eight
patients, five still maintained their PTH concentration
below the concentrations measured at the time point
when cinacalcet was discontinued. Serum calcium
concentrations were normal in four of these eight
patients and exceeded the upper limit of 2.6mmol/l in
the remaining four patients.
Effect of cinacalcet withdrawal on renal function
Serum creatinine concentrations ranged from 89 to
229 mmol/l with a median of 113 mmol/l (normal range
45–104mmol/l) before cinacalcet therapy. In seven of
the 10 patients, serum creatinine concentrations
increased during the 12 months on cinacalcet therapy
(Figure 2; see month 12 and 0). Following cinacalcet
withdrawal the concentrations declined again in seven
out of 10 patients during the following 3 months. In
three patients, serum creatinine slightly increased.
Two of these patients were prescribed an increasing
dose of an ACE inhibitor or angiotensin II receptor
antagonist. Mean creatinine clearance calculated
by the MDRD formula was 51.11 4.22ml/min/
1.73m2 when starting treatment with cinacalcet,
47.97 4.26ml/min/1.73m2 after 1 year of therapy
with cinacalcet and 52.42 5.86ml/min/1.73m2,
3 months after cessation of the drug. The differences
were not significant. In order to add an additional
independent parameter of the glomerular filtration
rate, cystatin C concentrations were determined at the
end of cinacalcet therapy and thereafter (Figure 2).
Cystatin C decreased after cessation of cinacalcet in 9
out of 10 patients within 3 months (month 0 vs month
3: 1.55 0.09 vs 1.33 0.12mg/l, P < 0.01, normal
range 0.63–1.44mg/l), suggesting an improvement of
the glomerular filtration rate. Cystatin C levels before
treatment were not measured routinely and are there-
fore not available.
At month 9 after cessation of cinacalcet two patients
were taking cinacalcet again. In six of the remaining
eight patients serum creatinine concentrations were
lower and in two, higher than at the end of cinacalcet
therapy. Cyclosporine A through levels as well as
blood pressure remained stable throughout the obser-
vation period. No side effects attributable to cinacalcet
withdrawal were encountered.
Discussion
In the present study, we report the effect of an
extended treatment with cinacalcet and its withdrawal
in renal transplant patients with persistent hyper-
parathyroidism. Three months after cessation of a
1 year lasting calcimimetic therapy serum calcium
concentrations remained normal in eight patients and
only slightly increased to 2.6mmol/l in two out of
10 patients. Similarly, PTH levels remained below the
concentrations encountered before cinacalcet therapy
was initiated in eight out of 10 patients. Based on the
present investigation, we cannot unambiguously estab-
lish whether the persistent improvement of the
hyperparathyroidism in our patients was due to
the calcimimetic or to the natural history because of
the absence of a control group. Frequently, secondary
hyperparathyroidism spontaneously disappears
during the first year after renal transplantation.
Thereafter, the prevalence of persistent hyperparathy-
roidism was reported to remain stable [11]. Our
patients were transplanted for 1.3–13 years before
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Fig. 2. Mean ( SEM) serum concentrations of creatinine and
cystatin C before initiation (12), after 1 year of cinacalcet (0) and 2
weeks (0.5), 2 months (2) and 3 months (3) after cessation of
cinacalcet. P< 0.05 vs month 0. Upper limit of normal cystatin C
range is depicted by dotted line.
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cinacalcet was prescribed. Therefore, it is reasonable to
conclude that treatment with this drug appears to have
some efficacy, which is present beyond the duration of
the prescription.
The mechanism by which cinacalcet appears to
exhibit a PTH suppressive effect beyond the duration
of therapy remains to be clarified. Calcimimetics were
shown to attenuate the progression of parathyroid
hyperplasia in rats [9]. Whether the inhibition of
proliferation causes a reduction of the size of the
parathyroid glands in renal transplant patients with
persistent hyperparathyroidism awaits confirmation.
Recently, Rodriguez et al. [12] observed an increase of
the VDR expression in parathyroid cells of rats given
the calcimimetic R-568. It is unknown whether such an
effect of a calcimimetic, if present in humans, persists
beyond the time the drug was prescribed. Since the
principle ligand of VDR, 1.25-dihydroxyvitamin D
increased after cessation of cinacalcet in our patients, a
persistent VDR-mediated inhibition of PTH-synthesis
is an attractive hypothesis for the reduced PTH-release
after withdrawal of cinacalcet.
The effect of cinacalcet on renal function is of special
interest and difficult to dissect from other factors
modulating the glomerular filtration rate in renal
transplant patients. In our previous investigation, we
showed that the mean serum creatinine concentration
rose significantly from 140 15 mmol/l at baseline to
153 17 mmol/l at two and 148 46 mmol/l at 3 months
of treatment with cinacalcet [4]. Similarly, serum
creatinine concentrations tended to increase, albeit
not significantly, from 116.1 8.7 mmol/l at baseline to
127.6 11.1 mmol/l during a 26-week course of cina-
calcet in ten renal transplant patients reported by Serra
et al. [13]. On the other hand, Srinivas et al. [7] treated
ten patients for 3–18 months and observed a reduction
of mean serum creatinine concentration from 152 14
to 144 12 mmol/l during treatment. Given the small
number of patients observed and the controversial
results with respect to cinacalcet on renal function, the
present results derived from patients after discontinua-
tion of cinacalcet deserve special attention. In seven
out of 10 patients both, serum creatinine concentra-
tions and cystatin C declined and in two additional
patients cystatin C diminished while serum creatinine
concentrations increased slightly. The reversibility of
the impairment of renal function as assessed by
cystatin C after cinacalcet withdrawal suggests that
the impairment might be due to some haemodynamic
calcium or PTH mediated effects rather than structural
changes in the transplanted kidney. This is supported
by the observation of deterioration of renal function
and the influence of serum calcium and PTH after
surgical parathyroidectomy [14].
In conclusion, the preliminary results from the
present observational study suggest a therapeutic
effect of cinacalcet beyond the duration of therapy
and how long this effect persists has to be established.
Nevertheless, it is reasonable to consider a trial of
cinacalcet discontinuation in order to establish if stable
renal transplant patients still need this drug, possibly at
a higher dose or alternatively eventually require
surgical parathyroidectomy. The optimal time point
after starting cinacalcet therapy for such a trial of
discontinuation is unknown and deserves a prospective
controlled trial [13].
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